Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto, Srikanth Deenadayalan, Andrea Navarria, Keiji Nishijima, Yutaka Seino, Yasushi Fukushima, Yoshiyuki Hamamoto, A Hisatomi, Yumiko Ide, Satoshi Inoue, Tatsushi Kawada, H Kim, Arihiro Kiyosue, K Matoba, Osamu Matsuoka, H. Nishimura, Masahiro Noguchi, Takeshi Osonoi, Shojiro Sawada, Yoshiyuki Shibasaki, Koki Shin, Yuichiro Yamada